RP-HPLC comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-06-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
Seventeen yachts and 167 crew started the first race of 27,500 nmi (50,900 km), which began from Portsmouth, United Kingdom, on 8 September 1973. Approximately 3000 spectator boats set out to witness the historic start. The first race was won by Mexican amateur Ramón Carlín in a Swan 65 yacht, Sayula II. Sayula II was followed by Adventure, Grand Louis and Kriter. The original course was designed to follow the route of the square riggers, which had carried cargo around the world during the 19th Century. From 2001 the ownership of the race was taken over by Volvo and Volvo Cars and the race was renamed the 'Volvo Ocean Race'. Stopover ports were added in Germany, France, and Sweden being Volvo's three biggest car markets in Europe. Winning the race does not attract a cash prize, as the feat of competing is presented as sufficient reward. Many of the crew in the Volvo Ocean Race race crew other professional teams in other high-profile events, such as the Olympic Games, Sydney to Hobart Yacht Race, the America's Cup, or the Fastnet Race. The worst weather conditions are usually encountered in the Southern Ocean where waves sometimes top 150 feet (46 m) and winds can reach 70 knots (130 km/h). The 2017–18 race covered 45,000 nautical miles, which is the longest route in its history.
The trust's executive directors discussed involving the police but instead commissioned a review by the Royal College of Paediatrics and Child Health (RCPCH). Letby was taken off the unit on 30 June, and the hospital subsequently reduced cot capacity and raised the gestational‑age threshold for admissions. The RCPCH review began in September 2016. Its October report found no definitive explanation for the increased mortality rate but identified inadequate staffing and senior cover. It described concerns about Letby as subjective and unsupported by evidence. The trust's medical director asked consultant neonatologist Jane Hawdon to undertake detailed case reviews recommended by the RCPCH. Hawdon instead conducted a review of medical notes relating to 17 deaths and collapses; she was understood to have told the hospital's medical director that she had not been able to conduct the thorough review that the RCPCH had recommended due to not having had the time, and later said that she had not been "adequately briefed" about the concerns about Letby before she carried out her analysis. The report concluded that most of the deaths and collapses could be explained and might have been preventable with different care, while four warranted further local forensic review. Minutes of a subsequent board meeting recorded the medical director stating that the RCPCH and Hawdon reviews attributed the deaths to leadership and intervention issues; the board chair later said he had been misled about the depth of Hawdon's review.
The melanocortins are a family of neuropeptide hormones which are the ligands of the melanocortin receptors. The melanocortin system consists of melanocortin receptors, ligands, and accessory proteins. The genes of the melanocortin system are found in chordates. Melanocortins were originally named so because their earliest known function was in melanogenesis. It is now known that the melanocortin system regulates diverse functions throughout the body, including inflammatory response, fibrosis, melanogenesis, steroidogenesis, energy homeostasis, sexual function, and exocrine gland function. There are four endogenous melanocortin agonists which are derived from post-transcriptional processing of the precursor molecule proopiomelanocortin (POMC). They are adrenocorticotropic hormone (ACTH), α-melanocyte stimulating hormone (MSH), β-MSH, and γ-MSH. In addition to agonists which activate melanocortin receptors, there are two antagonists which inhibit receptor activity, agouti-signaling protein (ASIP) and agouti-related protein (AgRP). Lastly, the ligand β-defensin 3 acts as a neutral melanocortin receptor antagonist.
She gained information about nine people, including the names of four of those killed, and found that some of "the dead men had indeed been running drugs but were not narco-terrorists ... or leaders of a cartel or gang". People interviewed by Garcia Cano said most of those killed were first-time crew members, and that they "included a fisherman, a motorcycle taxi driver, laborers and two low-level career criminals ... One was a well-known local crime leader who had agreed to work for narcotics smugglers." One reportedly trafficked both drugs and humans. Two unidentified bodies suspected by locals to be casualties from the 1 September strike washed up on the shores of Trinidad and Tobago, showing signs of having been blown up. People who knew him claimed one of the bodies was a Venezuelan, recognizable by his watch; the Associated Press report said "he had been jailed by Venezuelan authorities on human-trafficking charges after a boat he had operated capsized in December 2020" and people had described him as "a longtime local crime boss [who] made most of his living smuggling drugs and people across borders". Two days after the 6 November 2025 strike, a boat matching the one in the video of the strike washed ashore in the Guajira Peninsula of northwestern Colombia, near the Gulf of Venezuela, followed by bodies and charred debris, according to The New York Times. Two bodies that washed ashore were later buried by locals but, due to the remoteness of the area, did not come to media attention until the 29 December Times report.
However, the mass of an atomic-scale object is affected by the binding energy of the nucleons in its atomic nuclei, as well as the mass and binding energy of its electrons. Therefore, this equality holds only for the carbon-12 atom in the stated conditions, and will vary for other substances. For example, the mass of an unbound atom of the common hydrogen isotope (hydrogen-1, protium) is 1.007825032241(94) Da, the mass of a proton is 1.0072764665789(83) Da, the mass of a free neutron is 1.00866491606(40) Da, and the mass of a hydrogen-2 (deuterium) atom is 2.014101778114(122) Da. In general, the difference (absolute mass excess) is less than 0.1%; exceptions include hydrogen-1 (about 0.8%), helium-3 (0.5%), lithium-6 (0.25%) and beryllium (0.14%). The dalton differs from the unit of mass in the system of atomic units, which is the electron rest mass (me).
Sources: en.wikipedia.org
These compounds are promising anti-cancer and anti-fibrosis agents, inhibiting various protein tyrosine kinases. They have higher efficiency, lower toxicity, fewer side effects, favorable preparation technology and favorable physicochemical properties.
Combining these alongside psychotherapies like CBT may lead to better outcomes for BED. GLP-1 receptor agonist medications such as semaglutide (Ozempic), dulaglutide (Trulicity), and liraglutide (Saxenda) have been used for treating BED in recent years. Often prescribed for lowering appetite and subsequent weight loss in people with diabetes mellitus and obesity, they can successfully stop or reduce obsessive thoughts about food, binging urges, and other impulsive behaviors. Some users, reported sudden improvement in "food noise" - constant unstoppable thoughts about food, even not being physically hungry, which can be a symptom of BED. To this promising treatment is on the up for success, but additional research is needed as of January 2024.
== Support-free liquid chromatography == Standard column chromatography consists of a solid stationary phase and a liquid mobile phase, while gas chromatography (GC) uses a solid or liquid stationary phase on a solid support and a gaseous mobile phase. By contrast, in liquid-liquid chromatography, both the mobile and stationary phases are liquid. The contrast is, however, not as stark as it first appears. In reversed-phase chromatography, for example, the stationary phase can be regarded as a liquid which is immobilized by chemical bonding to a micro-porous silica solid support. In countercurrent chromatography centripetal or gravitational forces immobilize the stationary liquid layer. By eliminating solid supports, permanent adsorption of the analyte onto the column is avoided, and a high recovery of the analyte can be achieved. The countercurrent chromatography instrument is easily switched between normal phase chromatography and reversed-phase chromatography simply by changing the mobile and stationary phases. With column chromatography, the separation potential is limited by the commercially available stationary phase media and its particular characteristics. Nearly any pair of immiscible solutions can be used in countercurrent chromatography provided that the stationary phase can be successfully retained. Solvent costs are also generally lower than for HPLC. In comparison to column chromatography, flows and total solvent usage can in most countercurrent chromatography separations may be reduced by half and even up to a tenth.
=== Molecular classification === As with bacterial classification, identification of bacteria is increasingly using molecular methods, and mass spectroscopy. Most bacteria have not been characterised and there are many species that cannot be grown in the laboratory. Diagnostics using DNA-based tools, such as polymerase chain reaction, are increasingly popular due to their specificity and speed, compared to culture-based methods. These methods also allow the detection and identification of "viable but nonculturable" cells that are metabolically active but non-dividing. The main way to characterize and classify these bacteria is to isolate their DNA from environmental samples and mass-sequence them. This approach has identified thousands, if not millions of candidate species. Based on some estimates, more than 43,000 species of bacteria have been described, but attempts to estimate the true number of bacterial diversity have ranged from 107 to 109 total species—and even these diverse estimates may be off by many orders of magnitude.
Sources: en.wikipedia.org
Migraine is a complex pain disorder involving both blood vessels and neurons within the meninges, the brain's protective layers. The system involved is sometimes referred to as the trigeminovascular system. The trigeminal nerve, located within the dura mater, carries sensory information about pain, touch, heat, and cold from the face to the brain. The hypothalamus receives input from the trigeminal nerve and can modulate its activity. Individuals with migraine appear to experience impairments in cortical habituation, a process which would normally decrease the brain's response to repetitive sensory stimuli. Migraine attacks may begin with disruption in the hypothalamus and limbic system. Gradually increasing hypothalamic activity has been observed in the period leading up to a migraine attack, followed by a disruption or collapse of hypothalamic connectivity to the limbic system during an attack. Disruption of the connection between the hypothalamus and limbic system may increase activity in the pain pathway from the trigeminal nerve to the brain, resulting in a migraine attack. The meninges, particularly the dura mater, are rich in pain-sensitive nerve endings. Sensory information travels along trigeminal nerve fibers to cell bodies located within the trigeminal ganglion. Axons of the trigeminal ganglion (TG) neurons enter the brainstem and travel to the trigeminal nucleus caudalis (TNC). The activity of calcitonin gene-related peptide (CGRP) in the meninges is linked to migraine.
== See also == Blood–air barrier, also known as alveolar–capillary barrier – Membrane separating alveolar air from blood in lung capillaries Capillary refill – Medical term Hagen–Poiseuille equation – Law describing the pressure drop in an incompressible and Newtonian fluid Surface chemistry of microvasculature
A linear series of three quadrupoles is known as a triple quadrupole mass spectrometer. The first (Q1) and third (Q3) quadrupoles act as mass filters, and the middle (q2) quadrupole is employed as a collision cell. This collision cell is an RF-only quadrupole (non-mass filtering) using Ar, He, or N2 gas (~10−3 Torr, ~30 eV) for collision induced dissociation of selected parent ion(s) from Q1. Subsequent fragments are passed through to Q3 where they may be filtered or fully scanned. This process allows for the study of fragments that are useful in structural elucidation by tandem mass spectrometry. For example, the Q1 may be set to 'filter' for a drug ion of known mass, which is fragmented in q2. The third quadrupole (Q3) can then be set to scan the entire m/z range, giving information on the intensities of the fragments. Thus, the structure of the original ion can be deduced. The arrangement of three quadrupoles was first developed by Jim Morrison of La Trobe University in Australia for the purpose of studying the photodissociation of gas-phase ions. The first triple-quadrupole mass spectrometer was developed at Michigan State University by Christie Enke and graduate student Richard Yost in the late 1970s. Quadrupoles can be used in hybrid mass spectrometers. For example, a sector instrument can be combined with a collision quadrupole and quadrupole mass analyzer to form a hybrid instrument.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.